PMID- 33925605
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240402
IS  - 2076-3921 (Print)
IS  - 2076-3921 (Electronic)
IS  - 2076-3921 (Linking)
VI  - 10
IP  - 5
DP  - 2021 Apr 27
TI  - Nanotechnology-Based Drug Delivery to Improve the Therapeutic Benefits of NRF2 
      Modulators in Cancer Therapy.
LID - 10.3390/antiox10050685 [doi]
LID - 685
AB  - The disadvantages of conventional anticancer drugs, such as their low 
      bioavailability, poor targeting efficacy, and serious side effects, have led to 
      the discovery of new therapeutic agents and potential drug delivery systems. In 
      particular, the introduction of nano-sized drug delivery systems (NDDSs) has 
      opened new horizons for effective cancer treatment. These are considered 
      potential systems that provide deep tissue penetration and specific drug 
      targeting. On the other hand, nuclear factor erythroid 2-related factor 2 
      (NRF2)-based anticancer treatment approaches have attracted tremendous attention 
      and produced encouraging results. However, the lack of effective formulation 
      strategies is one of the factors that hinder the clinical application of NRF2 
      modulators. In this review, we initially focus on the critical role of NRF2 in 
      cancer cells and NRF2-based anticancer treatment. Subsequently, we review the 
      preparation and characterization of NDDSs encapsulating NRF2 modulators and 
      discuss their potential for cancer therapy.
FAU - Sezgin-Bayindir, Zerrin
AU  - Sezgin-Bayindir Z
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, 
      06560 Ankara, Turkey.
FAU - Losada-Barreiro, Sonia
AU  - Losada-Barreiro S
AUID- ORCID: 0000-0002-9447-5626
AD  - REQUIMTE-LAQV, Department of Chemistry and Biochemistry, Faculty of Sciences, 
      University of Porto, 4169-007 Porto, Portugal.
AD  - Department of Physical Chemistry, Faculty of Chemistry, University of Vigo, 36200 
      Vigo, Spain.
FAU - Bravo-Diaz, Carlos
AU  - Bravo-Diaz C
AUID- ORCID: 0000-0002-9468-0881
AD  - Department of Physical Chemistry, Faculty of Chemistry, University of Vigo, 36200 
      Vigo, Spain.
FAU - Sova, Matej
AU  - Sova M
AUID- ORCID: 0000-0002-8977-3450
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of 
      Ljubljana, Askerceva 7, 1000 Ljubljana, Slovenia.
FAU - Kristl, Julijana
AU  - Kristl J
AUID- ORCID: 0000-0001-9136-6507
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, University of 
      Ljubljana, Askerceva 7, 1000 Ljubljana, Slovenia.
FAU - Saso, Luciano
AU  - Saso L
AUID- ORCID: 0000-0003-4530-8706
AD  - Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza 
      University, P.le Aldo Moro 5, 00185 Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210427
PL  - Switzerland
TA  - Antioxidants (Basel)
JT  - Antioxidants (Basel, Switzerland)
JID - 101668981
PMC - PMC8145905
OTO - NOTNLM
OT  - NRF2 modulators
OT  - anticancer agents
OT  - drug delivery
OT  - drug targeting
OT  - nanoparticles
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/01 06:01
PMCR- 2021/04/27
CRDT- 2021/04/30 01:32
PHST- 2021/03/10 00:00 [received]
PHST- 2021/04/22 00:00 [revised]
PHST- 2021/04/23 00:00 [accepted]
PHST- 2021/04/30 01:32 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/01 06:01 [medline]
PHST- 2021/04/27 00:00 [pmc-release]
AID - antiox10050685 [pii]
AID - antioxidants-10-00685 [pii]
AID - 10.3390/antiox10050685 [doi]
PST - epublish
SO  - Antioxidants (Basel). 2021 Apr 27;10(5):685. doi: 10.3390/antiox10050685.